

JEFFREY S. GITT, DO

Curriculum Vitae

Signature/ Date

Office Locations

Jeffrey S. Gitt, DO, PC
3815 E. Bell Rd #2400
Phoenix, AZ 85032
Phone (602) 482-2116
Fax (602) 482-9563

HOPE Research Institute
3120 E. Union Hills Drive
Phoenix, AZ 85050
Phone (602) 288-4673
Fax (602) 288-4678
Website: www.hriaz.com

EDUCATION

- 1984 – 1987 Georgetown University Medical Center
Washington, D.C.
Resident in Neurology
Chief Resident in Neurology
Neurology Residency
- 1983 – 1984 Phoenix General Hospital
Phoenix, AZ
Rotating Internship
- 1979 – 1983 College of Osteopathic Medicine of the Pacific
Pomona, CA
Doctorate of Osteopathic Medicine
- 1977 – 1979 University of Michigan
Ann Arbor, MI
Bachelor of Science – Anthropology/Zoology
- 1975 – 1977 Michigan State University
East Lansing, MI
Major Physiology

CERTIFICATIONS & LICENSURE

- State Medical Licensure, Maryland (inactive)
State Medical Licensure, Arizona (active)
Drug Enforcement Agency 223 (active)
Multiple Sclerosis Certified Specialist, Consortium of Multiple
Sclerosis Centers
- 1989 Diplomate, American Board of Sleep Medicine
- 1990 Diplomate, American Board of Psychiatry and Neurology

JEFFREY S. GITT, DO

Curriculum Vitae

PROFESSIONAL SOCIETIES & MEMBERSHIPS

Arizona Osteopathic Medical Association
American Academy of Neurology
American Sleep Disorders Association
Arizona Neurologic Association
National Multiple Sclerosis Society, AZ
Member, Clinical Advisory Committee

LANGUAGES

English, Spanish

HOSPITAL PRIVILEGES

John C. Lincoln Hospital, North Mountain Campus (current)
Scottsdale Healthcare, Shea Campus (current)

PROFESSIONAL EXPERIENCE

1987 – 1993	Physician, Private Practice, Associates in Neurology, Scottsdale, AZ
1989 – present	Clinical Assistant Professor in Neurology, College of Osteopathic Medicine of the Pacific, Pomona, CA
1993 – present	Physician, Private Practice, North Valley Neurology & Sleep, Phoenix, AZ
1996 – 2003	Medical Director, Sleep Disorder Center, Scottsdale Healthcare, Shea Campus, Scottsdale, AZ
2002 – present	Investigator, HOPE Research Institute, Phoenix, AZ
2006 – present	Clinical Assistant Professor in Neurology, Midwestern University College of Osteopathic Medicine, Glendale, AZ
2011 – present	Medical Director, Arete Sleep Health, Scottsdale, AZ
2008 – 2009	Medical Director, Complete Sleep Analysis, Phoenix, AZ

HONORS/AWARDS

Phoenix Magazine, Top Doc 2011

SPEAKERS BUREAU

GlaxoSmithKline
Allergan Pharmaceuticals
Pfizer
EMD Serono
TEVA Neuroscience

JEFFREY S. GITT, DO

Curriculum Vitae

SPEAKERS BUREAU continued

Bayer
Biogen - Idec.
Novartis
Acorda Pharmaceuticals

PUBLICATIONS

J.S. GITT, DO, C.B. WATSON, DO, "Restless Legs Syndrome (RLS) Symptom Improvement With Ropinirole in RLS Patients With Disturbed Sleep," The Journal of American Osteopathic Association, August 2006; 106:8: 489-490

HOUFF, GITT, ET AL, "Involvement of JC Virus-Infected Mononuclear Cells from the Bone Marrow and Spleen in the pathogenesis of Progressive Multifocal Leukoencephalopathy," New England Journal of Medicine, February 4, 1988; 318:301-305

K. DOGHRAMJI, J.S. GITT, C. CHIANG, "Ropinirole in the long-term management of Restless Legs Syndrome: results from 52- and 36- week studies"

"Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy." Neurology 67, August (1 of 2) 2006; 400-406. Acknowledged contributor.

"Ropinirole in the Treatment of Patients with Restless Legs Syndrome: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial." Mayo Clinic Proc., January 2006; 81(1):17-27. Member, TREAT RLS US Study Group.

"Fluconazole Therapy for Coccidioidal Meningitis." Annals of Internal Medicine, July 1, 1993; 119(1):28-35. Acknowledged contributor.

POSTERS

Ropinirole CR- Extended- Release- Reduces Mood Disturbances in Subjects with Moderate -to-Severe Primary Restless Legs Syndrome (RLS): Results from a 12-week Pivotal Trial

Ropinirole CR Extended-Release Treatment Improves both the Symptoms and the Impact of Restless Legs Syndrome

RESEARCH EXPERIENCE

Arizona Medical Association Study of Epidural Steroid Use for the Treatment of Low Back Pain

XXX versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder

JEFFREY S. GITT, DO

Curriculum Vitae

RESEARCH EXPERIENCE (continued)

Double-Blind Randomized Trial of Cognitive Effects of XXX versus XXX in Epilepsy

A Phase III, Open-Label, Outpatient, Extension Study To Assess The Long-Term Safety Of A Modified Release Formulation Of XXX in Adult Primary Insomnia Patients With Sleep Maintenance Difficulties

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study To Assess The Efficacy And Safety Of A Modified Release Formulation Of XXX in Adult Primary Insomnia Patients With Sleep Maintenance Difficulties

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study To Assess The Efficacy And Safety Of A Modified Release Formulation Of XXX in Elderly Primary Insomnia Patients With Sleep Maintenance Difficulties

A Phase III, Open-Label, Outpatient, Extension Study to Assess the Long-Term Safety Of A Modified Release Formulation Of XXX in Elderly Primary Insomnia Patients With Sleep Maintenance Difficulties

Safety Evaluation Of XXX With XXX In Opioid Tolerant Patients

Open-Label Safety Evaluation of XXX With XXX In Opioid Tolerant Patients

A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation Of The Safety And Efficacy Of XXX In Patients With Severe Alzheimer's Disease Followed By A 12-Week Open-Label Extension Period

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing XXX 150 Mg, 300 Mg, and 600 Mg To Placebo and XXX 150 Mg In Patients With Mild-to-Moderate Essential Hypertension

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study To Assess The Long-Term Safety And Efficacy Of Two Dose Levels Of A Modified Release Formulation Of XXX In Adult Patients With Primary Insomnia

A Multi-Center, Open-Label, Pilot Study Of XXX As Adjunctive Therapy And Monotherapy In Patients With Epilepsy And Comorbid Depressive Symptoms

A Phase III Pivotal, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Mono-Therapy Study of XXX For Treatment Of Fibromyalgia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Attack Study To Evaluate The Onset Of Efficacy Of A New Formulation Of XXX Tablets 50mg And 100mg In The Acute Treatment of Migraine

XXX In Post-Herpetic Neuralgia: A Multi-Center, Placebo-Controlled, 3-Week Dose-Finding Study, With A 3-Week Active Treatment Extension

JEFFREY S. GITT, DO

Curriculum Vitae

RESEARCH EXPERIENCE (continued)

A Randomized, Double-Blind, Controlled Study Of XXX For The Treatment of Post-Herpetic Neuralgia

A 12-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy And Safety Of XXX In Patients Suffering With Restless Leg Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of XXX For The Treatment Of Painful Diabetic Neuropathy

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial To Assess The Efficacy And Safety of 200, 400, And 600Mg/Day Of XXX In Subjects With Painful Distal Diabetic Neuropathy

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study To Assess The Efficacy And Safety Of A Modified Release Formulation Of XXX In Adult Primary Insomnia Patients With Sleep Maintenance Difficulties

Dose Response Study Of XXX Versus Placebo In The Treatment Of Fibromyalgia Syndrome

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing The Safety And Efficacy Of XXX In Patients With Post-Herpetic Neuralgia

A Phase III, Multi-Center, Double-Blind, Randomized, Mono-Therapy Extension Study Of XXX For Treatment Of Fibromyalgia

A Double-Blind, Phase II, Safety And Efficacy Evaluation Of XXX In Patients With Mild To Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase IIb Study To Evaluate The Efficacy And Safety Of Multiple XXX Dosage Regimens For The Treatment Of Opioid-Induced Bowel Dysfunction In Subjects With Chronic Pain Of Non-Malignant Origin

A randomized, double-blind, placebo-controlled, parallel Group phase 2 study to evaluate the safety and efficacy of XXX in subjects with mild to moderate Alzheimer's disease

A 13-Week Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial Of XXX In Patients With Fibromyalgia

A Long-Term, Open-Label, Safety Trial Of XXX In Patients With Fibromyalgia

A Double-Blind, Placebo-Controlled, Multi-Center, Multi-National Phase III Study To Evaluate The Safety And Efficacy Of XXX 1mg B.I.D. In Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

A 12 Week, Double-Blind, Placebo-Controlled, Twice Daily Dosing Study To Assess The Efficacy And Safety Of XXX In Patients Suffering From Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

JEFFREY S. GITT, DO

Curriculum Vitae

RESEARCH EXPERIENCE (continued)

A Randomized, Double-Blind, Placebo-Controlled Study To Assess The Subjective Response To Treatment With XXX In Adult Subjects With Chronic Insomnia By Utilizing An Interactive Voice Response System (IVRS) For Collecting Diary Data

A 12 Week, Double-Blind, Placebo-Controlled Study To Assess The Tolerability, Efficacy And Safety Of XXX Dosed PRN In Subjects With Restless Legs Syndrome (RLS) Who Respond To Open-Label Treatment With XXX (Treat RLS PRN)

A Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of XXX Extended Release Tablets In The Treatment Of Patients with Postherpetic Neuralgia

A 12 Week, Double-Blind, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy And Safety Of XXX In Patients With Restless Legs Syndrome

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study To Assess The Safety And Efficacy Of XXX In Subjects With Low Back Pain

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Two-Week Study To Assess The Safety And Efficacy Of XXX In Subjects with Pain from Moderate Lateral Epicondylitis

Dose Response Study Of XXX Versus Placebo In The Treatment Of Fibromyalgia Syndrome

A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated With XXX

An Open-Label Safety Study with Intermittent Use of XXX in Subjects with Lower Back Pain, Pain from Osteoarthritis of the Knee, Shoulder Pain or Lateral Epicondylitis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of XXX 0.5mg Twice Daily For 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain

An Open-Label, Multi-Center, Multinational Phase III Follow-Up Study To Investigate The Long-Term Safety And Efficacy Of XXX 1mg B.I.D. in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

A Short-Term (8-Week) Open-Label Study, Followed By A Long-Term Evaluation, To Assess Patient Satisfaction With XXX For Excessive Sleepiness In Adults With Narcolepsy Or Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study To Determine The Consistency Of Response for XXX, XXX, XXX Administered During The Mild Pain Phase For The Acute Treatment Of Multiple Migraine Attacks

A 52-Week, Open-Label Study to Assess the Long-Term Safety of XXX Extended Release (XR) In Patients with Restless Legs Syndrome (RLS)

JEFFREY S. GITT, DO

Curriculum Vitae

RESEARCH EXPERIENCE (continued)

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Proof-Of-Concept Study to Evaluate the Safety and Efficacy of XXX Taken In Combination with XXX for the Treatment of Subjects with Chronic Insomnia

A Two-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Efficacy and Safety, Out-Patient Trial with XXX in Patients with Chronic Primary Insomnia

Phase 3 Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in the Treatment of Patients with Postherpetic Neuralgia

A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of XXX Extended Release Tablets Compared with XXX Immediate Release (IR) Tablets in Subjects with Restless Legs Syndrome (RLS)

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous XXX in Subjects with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Tolerability of XXX for a Single Moderate or Severe Headache in Adults Diagnosed with Probable Migraine without Aura

Efficacy and Safety of XXX on Sleep Maintenance Insomnia: a 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

A Multi-Center, Open-Label Study of the Safety and Efficacy of Long Term Use of XXX in the Treatment of Patients with Postherpetic Neuralgia

Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral XXX (10 mg b.i.d.) in Patients with Multiple Sclerosis

A Phase IV, Randomized, Double-Blind, Active and Placebo-Controlled, 6-Week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose of XXX in Patients with Idiopathic Restless Legs Syndrome

A 54-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of XXX (Extended Release Tablets) as Adjunctive Therapy to XXX on Cognition and Overall Clinical Response in APOE ϵ 4-Stratified Subjects with Mild to Moderate Alzheimer's Disease

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Fourteen Day Treatment with XXX or XXX Once a Day in Frequent Nighttime Heartburn

Open-Label, Multicenter, Effectiveness and Safety Study of Once Daily XXX as Mono or Adjunct Therapy in Patients with Idiopathic Parkinson's Disease (PD)

Efficacy and Safety of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX on Stable Type II Diabetes Mellitus: A One Year, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study

JEFFREY S. GITT, DO

Curriculum Vitae

RESEARCH EXPERIENCE (continued)

A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Multiple Doses of XXX Sustained Release (SR)/XXX Sustained Release (SR) and Placebo in Obese Subjects with Type 2 Diabetes Mellitus.

A Randomized, Multicenter, Two-Arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QoL) Measures in Subjects with Relapsing Forms of Multiple Sclerosis Who are Transitioning from XXX to XXX New Formulation

Open-Label Extension Study to Evaluate the Safety, Tolerability, and Activity of Oral XXX in Patients with Multiple Sclerosis who Participated in the XXX Trial

Randomized, Double Blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized XXX West Nile Vaccine in Healthy Adults

XXX Dose-Ranging Trial; A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial of XXX in Adults with Primary Insomnia

A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of XXX Sustained Release (SR)/XXX Sustained Release (SR) and Placebo in Obese Subjects

Psychometric Validation of the Assessment of Sleep Questionnaire and the Daytime Consequences of Insomnia Questionnaire

An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous XXX in Subjects previously treated in the XXX Study

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of XXX in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein Not E ϵ 4 Carriers

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of XXX in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E ϵ 4 Carriers

A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of XXX monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course

A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of XXX over placebo in a double-blind design and of a reference arm of XXX, in a rater-blinded design

Flexible Dosed XXX Versus Placebo In the Treatment of Fibromyalgia

JEFFREY S. GITT, DO

Curriculum Vitae

A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of XXX in Subjects With Relapsing-Remitting Multiple Sclerosis

RESEARCH EXPERIENCE (continued)

A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator-controlled Study of the Safety and Efficacy of XXX in Outpatients with Insomnia

A Phase 3, Randomized, Rater and Dose Blinded Study Comparing Two Annual Cycles of Intravenous Low and High Dose XXX to Three Times Weekly Subcutaneous XXX in Patients with Relapsing Remitting Multiple Sclerosis who have Relapsed on Therapy.

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of XXX for a single moderate or severe headache in adults diagnosed with probable migraine.

Assessment of the effect of XXX tablet, XXX tablet and XXX tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults

A Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Parkinson's Disease.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral XXX in Subjects with a First Clinical Event at High Risk of Converting to MS

A Randomized Double Blind Placebo Controlled Four Week Study of the Efficacy and Safety of Four Doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of XXX tablets vs. Placebo in Idiopathic Restless Legs Syndrome.

Chronic Migraine Treatment Trial

An Open-Label, Multicenter Phase II extension of Study XXX to Obtain Long-Term Follow-Up Data in Subjects with Relapsing Multiple Sclerosis Treated with XXX for Up to 5 Years (XXX-Extension).

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre, Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of XXX with One-Dose Escalation Compared to Placebo in Peripheral Neuropathic Pain Patients with Mechanical Hypersensitivity

A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of XXX in Subjects with Alzheimer's Disease who Participated in Study XXX or in Study XXX

A Randomized, Double-Blind, Placebo and Active Controlled, Study of the Safety and Efficacy of XXX in Patients with Diabetic Peripheral Neuropathic Pain

A 12-Month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of XXX in Subjects Who Are at Risk for Developing Aspirin-associated Gastric Ulcers

JEFFREY S. GITT, DO

Curriculum Vitae

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of XXX in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers

RESEARCH EXPERIENCE (continued)

The Effect of the Dose of XXX on Efficacy, Safety, and Tolerability in Subjects with the Relapsing Remitting Form of Multiple Sclerosis. A Phase 2a Randomized, double-blind, four-arm, parallel, placebo-controlled and active descriptive-comparator, 40 week trial

A Multinational, Multicenter, Open-Label, Single-Assignment Extension of the XXX Study, to Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course of Daily Oral XXX 0.6 mg in Subjects with Relapsing Multiple Sclerosis

An Open-Label Extension Study of the Safety and Clinical Utility of XXX in Subjects with Parkinson's Disease

RANDOMIZED, DOUBLE-BLIND, 12-WEEK STUDY OF XXX IN SUBJECTS WITH RESTLESS LEGS SYNDROME

A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of XXX injection 40 mg/ml administered three times a week compared to placebo in a double-blind design

JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With XXX.

An Extension Protocol for Multiple Sclerosis Patients Who Participated in XXX Sponsored Studies of XXX (e.g. XXX, XXX or XXX)

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of XXX for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine

An Open-Label, Multicenter Study in Subjects with Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg XXX TID Administered as Add-On Therapy to XXX or XXX

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Adaptive Design Phase 2 Study of Three Different Doses of an XXX or Placebo in Subjects with Mild to Moderate Probable Alzheimer's Disease

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of XXX/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (XXX)

Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of XXX versus XXX in Patients with Relapsing-Remitting Multiple Sclerosis

JEFFREY S. GITT, DO

Curriculum Vitae

A Phase III, randomised, double blind and open label phase, active and placebo controlled study comparing the short term efficacy of two formulations of XXX to placebo, and assessing the short and long term efficacy and safety of XXX following repeated treatments of subjects with cervical dystonia (CD).

RESEARCH EXPERIENCE (continued)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of XXX in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers XXX

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in XXX Clinical Trials